Clinical Trial Update: Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 [NA]

View source ↗

Summary

A Memorial Sloan Kettering trial evaluated whether pretreatment with the MEK inhibitor selumetinib (AZD6244) can restore radioactive iodine uptake in metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Radioiodine-refractory Differentiated Thyroid Cancer

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Thyroid Cancer | NA | Status: COMPLETED | Results posted: 2017-04-12